Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Immunology

• Publication date

  2000-02-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.164.4.2160PMID 10657670
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 11th International Congress of Immunology

  2001cited by this paper
• Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion1

  2000cited by this paper
• Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.

  1999cited by this paper
• CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor, Blr-1

  1998cited by this paper
• OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors.

  1998cited by this paper
• OX-40: life beyond the effector T cell stage.

  1998cited by this paper
• Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.

  1998cited by this paper
• The Central Role of CD4+ T Cells in the Antitumor Immune Response

  1998cited by this paper
• Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.

  1998influential reference
• Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.

  1998cited by this paper
• The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells.

  1998influential reference
• Role of 4-1BB in immune responses.

  1998cited by this paper
• Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance.

  1998cited by this paper
• CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

  1998cited by this paper
• The host-tumor immune conflict: from immunosuppression to resistance and destruction.

  1997cited by this paper
• Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.

  1997cited by this paper
• Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

  1997cited by this paper
• 4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses

  1997cited by this paper
• Unequal Death in T Helper Cell (Th)1 and Th2 Effectors: Th1, but not Th2, Effectors Undergo Rapid Fas/FasL-mediated Apoptosis

  1997cited by this paper
• Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers.

  1997cited by this paper
• Expression and function of OX40 ligand on human dendritic cells.

  1997cited by this paper
• OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand

  1996cited by this paper
• Vβ CDR3 motifs associated with BP recognition are enriched in OX‐40+ spinal cord T cells of lewis rats with EAE

  1996influential reference
• CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

  1996cited by this paper
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

  1996cited by this paper
• The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells

  1996cited by this paper
• OX‐40 antibody enhances for autoantigen specific Vβ8.2+ T cells within the spinal cord of lewis rats with autoimmune encephalomyelitis

  1996cited by this paper
• Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.

  1996cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• Selective depletion of myelin–reactive T cells with the anti–OX–40 antibody ameliorates autoimmune encephalomyelitis

  1996cited by this paper
• Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.

  1996cited by this paper
• Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells.

  1995cited by this paper
• Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.

  1995cited by this paper
• Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice

  1995cited by this paper
• Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

  1995cited by this paper
• Early expression of cytokines in lymph nodes after treatment in vivo with Staphylococcus enterotoxin B.

  1994cited by this paper
• Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2.

  1994cited by this paper
• Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV‐1‐regulated protein gp34.

  1994cited by this paper
• CD27: marker and mediator of T-cell activation?

  1994cited by this paper
• A lymphotoxin-beta-specific receptor.

  1994cited by this paper
• Target organ-specific up-regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis.

  1994cited by this paper
• Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

  1994cited by this paper
• Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

  1993cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• CD40 ligand and its role in X-linked hyper-IgM syndrome.

  1993cited by this paper
• Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood.

  1992cited by this paper
• Incidence of c-Ki-ras activation in N-methyl-N-nitrosourea-induced mammary carcinomas in pituitary-isografted mice.

  1992cited by this paper
• Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

  1992cited by this paper
• Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

  1992cited by this paper
• Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax

  1991cited by this paper
• Molecular cloning and characterization of a novel glycoprotein, gp34 that is specifically induced by the human T-cell leukemia virus type I transactivator p40[tax]

  1991cited by this paper
• Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.

  1991cited by this paper
• Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts.

  1987cited by this paper
• Establishment of mouse colonic carcinoma cell lines with different metastatic properties.

  1980cited by this paper
• The selection and characterization of an invasive variant of the B16 melanoma.

  1979cited by this paper
• The Microincineration of Herpetic Intranuclear Inclusions.

  1933cited by this paper

• OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress

  2026cites this paper
• 模拟禁食饮食在肿瘤治疗中的作用：机制、挑战与临床前景

  2025cites this paper
• A novel anti-OX40 human monoclonal antibody that blocks OX40/OX40L signaling and depletes OX40+ T cells

  2025cites this paper
• Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches

  2025cites this paper
• Advancements in noninvasive visualization of the immune environment in glioblastoma: A systematic review

  2025cites this paper
• Enhanced Antitumor Immunity Through T Cell Activation with Optimized Tandem Double-OX40L mRNAs

  2025cites this paper
• In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinoma

  2025cites this paper
• Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes

  2025cites this paper
• Soluble B7 and TNF family in colorectal cancer: Serum level, prognostic and treatment value.

  2025cites this paper
• Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy

  2025cites this paper
• Making the effect visible – OX40 targeting nanobodies for in vivo imaging of activated T cells

  2024cites this paper
• Analysis of the expression of cytokines and chemokines, platelet‐leukocyte aggregates, sCD40L and sCD62P in cutaneous melanoma

  2024cites this paper
• OX40/OX40 ligand and its role in precision immune oncology

  2024cites this paper
• Prognostic Role of OX40, LAG-3, TIM-3 and PD-L1 Expression in Bone and Soft Tissue Sarcomas

  2024cites this paper
• Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer

  2024cites this paper
• In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma

  2024cites this paper
• Engineering antibodies with cancer‐associated binding sites

  2024cites this paper
• Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects

  2024cites this paper
• Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients

  2024cites this paper
• Challenges and opportunities in the development of combination immunotherapy with OX40 agonists

  2023cites this paper
• Prognostic Significance of the Microenvironment in Human Papillomavirus Oropharyngeal Carcinoma: A Systematic Review

  2023cites this paper
• T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.

  2023cites this paper
• Fcγ receptors and immunomodulatory antibodies in cancer

  2023cites this paper
• Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

  2022cites this paper
• Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

  2022cites this paper
• Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia

  2022cites this paper
• A multivariate modeling framework to quantify immune checkpoint context-dependent stimulation on T cells

  2022cites this paper
• Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy

  2022cites this paper
• First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

  2022cites this paper
• Emerging Trends in Immunotherapy for Cancer

  2022cites this paper
• OX40L enhances the immunogenicity of dendritic cells and inhibits tumor metastasis in mice

  2022cites this paper
• First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

  2022cites this paper
• Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors

  2022cites this paper
• A multivariate modeling framework to quantify immune checkpoint context-dependent stimulation on T cells

  2022cites this paper
• Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer

  2022cites this paper
• Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model

  2022cites this paper
• A concise review on the role of natural and synthetically derived peptides involved in colorectal cancer.

  2022cites this paper
• Basics of immunooncology and immunotherapy in oncology

  2022cites this paper
• Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects.

  2022cites this paper
• Non-negative matrix factorization model-based construction for molecular clustering and prognostic assessment of head and neck squamous carcinoma

  2022cites this paper
• Clinical Signi�cance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer

  2021cites this paper
• Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.

  2021cites this paper
• Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ

  2021cites this paper
• Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

  2021cites this paper
• A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity

  2021cites this paper
• Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome

  2021influential citation
• Fractional Laser Treatment Boosts Systemic Anti-Tumor Immunity in Combination with OX40 Agonist and PD-1 Blockade

  2021cites this paper
• Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients

  2021cites this paper
• Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer

  2021cites this paper
• A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

  2021cites this paper
• Novel immune targets for the treatment of triple-negative breast cancer

  2021cites this paper
• Nonnegative Matrix Factorization Model-Based Construction For Molecular Clustering and Prognostic Assessment of Squamous Carcinoma of Head and Neck

  2021cites this paper
• Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy

  2021cites this paper
• Checkpoint inhibition in the fight against cancer: NK cells have some to say in it

  2021cites this paper
• Co-stimulatory agonists: An insight into the immunotherapy of cancer

  2021cites this paper
• The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

  2021cites this paper
• Whole-body PET Imaging of T-cell Response to Glioblastoma

  2021cites this paper
• Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy

  2021cites this paper
• Laboratory biomarkers of an effective antitumor immune response. Clinical significance.

  2021cites this paper
• Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors

  2021cites this paper
• Immunology of Melanoma

  2020cites this paper
• Tumor Infiltration by OX40+ Cells Enhances the Prognostic Significance of CD16+ Cell Infiltration in Colorectal Cancer

  2020cites this paper
• OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity.

  2020cites this paper
• Improving responses to immunotherapy in head and neck squamous cell carcinoma

  2020cites this paper
• Narrative review of cytokines and cell surface markers in the tumor microenvironment of stage I lung cancer

  2020cites this paper
• Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

  2020cites this paper
• Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review

  2020cites this paper
• Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy

  2020cites this paper
• Bifunctional macromolecule activating both OX40 and interferon-α signaling displays potent therapeutic effects in mouse HBV and tumor models.

  2020cites this paper
• Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy.

  2020cites this paper
• Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy.

  2020cites this paper
• A guide to cancer immunotherapy: from T cell basic science to clinical practice

  2020cites this paper
• Overcoming Cancer Tolerance with Immune Checkpoint Blockade

  2020cites this paper
• Necroptotic‐susceptible dendritic cells exhibit enhanced antitumor activities in mice

  2020cites this paper
• CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement

  2020cites this paper
• Mechanisms of resistance to T cell‐based immunotherapy in head and neck cancer

  2020cites this paper
• New pathways in immune stimulation: targeting OX40

  2020cites this paper
• Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer

  2020cites this paper
• T Cell Dysfunction in Cancer Immunity and Immunotherapy

  2019cites this paper
• 5-1-2018 Potent Immune Modulation by MEDI 6383 , an Engineered Human OX 40 Ligand IgG 4 P Fc Fusion Protein

  2019cites this paper
• Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer.

  2019cites this paper
• High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer.

  2019cites this paper
• Immunotherapy in extensive small cell lung cancer

  2019cites this paper
• Immunotherapy for Head and Neck Cancer.

  2019cites this paper
• Cancer Immunotherapy Targeting Co-signal Molecules.

  2019cites this paper
• Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB

  2019cites this paper
• The Role of Tumor Necrosis Factor Receptor Superfamily Molecules on regulation of T cell response to Zika virus

  2019cites this paper
• High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer

  2019cites this paper
• Current Immunotherapy Approaches for Malignant Melanoma

  2019cites this paper
• Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy

  2019cites this paper
• INHIBITION OF UROTHELIAL CARCINOMA BY TYPE I INTERFERON ACTIVATION OF THE INNATE AND ADAPTIVE IMMUNE RESPONSE

  2019cites this paper
• Precision Medicine-Enabled Cancer Immunotherapy.

  2019cites this paper
• Immunotherapy for Head and Neck Cancer.

  2019cites this paper
• Immunological Treatment in Gastrointestinal Cancers

  2019cites this paper
• Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies.

  2019cites this paper
• OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer

  2019cites this paper
• Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity

  2019cites this paper
• OTT_A_214211 7347..7353

  2019cites this paper
• The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review.

  2019cites this paper
• Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein

  2018cites this paper